Literature DB >> 33420237

Factors associated with left ventricular reverse remodelling after percutaneous coronary intervention in patients with left ventricular systolic dysfunction.

Yusuke Adachi1, Arihiro Kiyosue2, Jiro Ando1, Takuya Kawahara3, Satoshi Kodera1, Shun Minatsuki1, Hironobu Kikuchi1, Toshiro Inaba1, Hiroyuki Kiriyama1, Kazutoshi Hirose1, Hiroki Shinohara1, Akihito Saito1, Takayuki Fujiwara1, Hironori Hara1, Kazutaka Ueda1, Kenichi Sakakura4, Masaru Hatano1,5, Mutsuo Harada1, Eiki Takimoto1, Hiroshi Akazawa1, Hiroyuki Morita1, Shin-Ichi Momomura4, Hideo Fujita1,4, Issei Komuro1.   

Abstract

Percutaneous coronary intervention (PCI) is sometimes considered as an alternative therapeutic strategy to surgical revascularization in patients with coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). However, the types or conditions of patients that receive the clinical benefit of left ventricular reverse remodelling (LVRR) remain unknown. The purpose of this study was to investigate the determinants of LVRR following PCI in CAD patients with reduced LVEF. From 4394 consecutive patients who underwent PCI, a total of 286 patients with reduced LV systolic function (LVEF < 50% at initial left ventriculography) were included in the analysis. LVRR was defined as LV end-systolic volume reduction ≥ 15% and improvement of LVEF ≥ 10% at 6 months follow-up left ventriculography. Patients were divided into LVRR (n = 63) and non-LVRR (n = 223) groups. Multivariate logistic regression analysis revealed that unprotected left main coronary artery (LMCA) intervention was significantly associated with LVRR (P = 0.007, odds ratios [OR] 4.70, 95% confidence interval [CI] 1.54-14.38), while prior PCI (P = 0.001, OR 0.35, 95% CI 0.19-0.66), presence of in-stent restenosis (P = 0.016, OR 0.32, 95% CI 0.12-0.81), and presence of de-novo stenosis (P = 0.038, OR 0.36, 95% CI 0.14-0.95) were negatively associated with LVRR. These data suggest the potential prognostic benefit of unprotected LMCA intervention for LVRR and importance of angiographic follow-up in patients with CAD and LV systolic dysfunction.

Entities:  

Year:  2021        PMID: 33420237      PMCID: PMC7794568          DOI: 10.1038/s41598-020-80491-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  33 in total

1.  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1997-02-08       Impact factor: 79.321

2.  Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data.

Authors:  Davide Capodanno; Gregg W Stone; Marie C Morice; Theodore A Bass; Corrado Tamburino
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

3.  Treatment of Left Main Coronary Artery Disease.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2016-10-31       Impact factor: 91.245

4.  Peripheral endothelial function may predict the effectiveness of beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.

Authors:  Xudong Xie; Bifeng Wu; Yao Chen; Wenyuan Li; Xiaosheng Hu; Junzhu Chen
Journal:  Int J Cardiol       Date:  2016-06-27       Impact factor: 4.164

5.  Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy.

Authors:  Cheuk-Man Yu; Gabe B Bleeker; Jeffrey Wing-Hong Fung; Martin J Schalij; Qing Zhang; Ernst E van der Wall; Yat-Sun Chan; Shun-Ling Kong; Jeroen J Bax
Journal:  Circulation       Date:  2005-09-06       Impact factor: 29.690

6.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

Authors:  R N Doughty; G A Whalley; G Gamble; S MacMahon; N Sharpe
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

7.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

Authors:  P Lechat; S Escolano; J L Golmard; H Lardoux; S Witchitz; J A Henneman; B Maisch; M Hetzel; P Jaillon; J P Boissel; A Mallet
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

8.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

Authors:  Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Alberto Volpi; Yann-Tong Chiang; Raymond L Benza; Sidney O Gottlieb; Thomas D Kleemann; Franco Rosconi; Pieter M Vandervoort; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

9.  Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.

Authors:  Marie-Claude Morice; Patrick W Serruys; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; James W Choi; Witold Ruzyllo; Grzegorz Religa; Jian Huang; Kristine Roy; Keith D Dawkins; Friedrich Mohr
Journal:  Circulation       Date:  2014-04-03       Impact factor: 29.690

10.  International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values.

Authors:  Atsunori Kashiwagi; Masato Kasuga; Eiichi Araki; Yoshitomo Oka; Toshiaki Hanafusa; Hiroshi Ito; Makoto Tominaga; Shinichi Oikawa; Mitsuhiko Noda; Takahiko Kawamura; Tokio Sanke; Mitsuyoshi Namba; Mitsuru Hashiramoto; Takayuki Sasahara; Yoshihiko Nishio; Katsuhiko Kuwa; Kohjiro Ueki; Izumi Takei; Masao Umemoto; Masami Murakami; Minoru Yamakado; Yutaka Yatomi; Hatsumi Ohashi
Journal:  J Diabetes Investig       Date:  2012-02-20       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.